Bald dürfte der Durchbruch geschafft sein - 500 Beiträge pro Seite

[nekro]

Kurs unter http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX

Company News unter http://finance.yahoo.com/q?d=t&s=BOCX.PK

Ist zwar noch ein PINKSHEET ,bei weiteren positiven News kann das sich aber sehr schnell ändern

Feature: BioCurex - Prostate Cancer Results Trump PSA Test.


BioCurex (BOCX.PK) has added prostate results to its list of cancers detected by its RECAF™ blood test. Along with the previous detection results for stomach, lung, ovarian, breast and colon, the company has added significant findings for the early detection of prostate cancer. Although prostate cancer represents only 17 percent of all cancers, the results (release below) continue to add validity to both the company’s biotechnology and its business plan.
That plan, of course, is to attract partners to license and further validate BioCurex’s products—a process that continues with ongoing discussions and information sharing with major healthcare companies and laboratories. We believe it is only a matter of time before these discussions bear fruit for the company and its shareholders.

For risk-oriented (and we mean risk-oriented) investors, we have suggested accumulation at these—and higher-- levels for a while now, and we see no reason to change that strategy.

BOCX Quote available here: (http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX )

As mentioned in the accompanying release, the company continues to use best efforts to return the shares to the OTCBB as soon as possible. As you’ll recall, they were halted and banished to the Pinks in April as a result of a regulatory inquiry with which the company has and continues to fully cooperate. The return to the OTCBB takes time, but management appears confident that they will be re-instated.

The posting on the Pinks has hurt the visibility of BioCurex. The shares have moved down to 50 cents recently, which appears to be a reasonable support level. Volumes have perked up of late and it appears the company is working hard to further validate its technology and attract partners. There is apparently good interest from potential partners and hopefully those discussions will result in tangible results soon.

As we’ve said before, all it would take is a deal or two to bring BioCurex the attention from peers and investors we continue to feel it deserves. We have seen in the past that there are lots of folks watching the company’s progress and waiting for news. The picture could well change overnight. We feel that BioCurex is well worth placement in the speculative end of a portfolio.

I won’t attempt to qualify the apparent superiority of BioCurex’s RECAF™ blood test over the standard PSA test for the detection of prostate cancer—the release is much more detailed and focused in that regard—I would urge you to give it a read.

Suffice to say, the PSA test has come under increased scrutiny lately from the medical community and should BioCurex’s test enhance or even replace PSA, it would obviously be a huge win for the company and for the survival rate of patients who may already have or become afflicted with this scourge in the future.

The bottomline is this: over the past year BioCurex has had its share of corporate challenges and could have used many opportunities to delay or even abandon its important work. Instead, management has continued to refine, research, develop and validate its products, as well as make every effort to inform the pharmaceutical and medical community of its work. As well, it continues to engage in promising ongoing discussions with potential partners.

That said remember that the company is still at a formative stage and must be classified as speculative at least until commercialization becomes a reality.

When will that be? Obviously we hope soon. Even if the company uses only half the effort to secure partners in the coming weeks and months as it has to continue its research and tell it’s story in the right quarters over the last year, we believe it will prosper.

Guaranteed? Of course not. However, from our vantage point, for those risk-oriented investors who share the vision, should the reality be realized, the potential reflection in the share price will be worthwhile for those holding shares or accumulating them over the past months.
Press Release Source: BioCurex, Inc.
Biocurex’s RECAF Blood Test Outperforms PSA For Prostate Cancer Detection

RICHMOND, British Columbia, November 30th, 2004. -- BioCurex Inc. (BOCX.PK - News) BioCurex Inc. is pleased to report its findings on RECAF[TM] serum testing of Prostate cancer specimens. Our results show that BioCurex’s RECAF serum test exhibited greater sensitivity and more importantly, much higher specificity than the currently used PSA test as shown in the table.



* Source: Figure 3, values at 4 ng/ml. Brawer MK., CA Cancer J Clin (American Cancer Society), 1999 Sep-Oct;49(5):264-81 (http://caonline.amcancersoc.org/cgi/reprint/49/5/264).
** Values from 77 known cancer patients were compared to 66 normal donors.
*** Values from 77 known cancer patients were compared to 65 patients with benign prostate tumors or hyperplasia.

According to the National Cancer Institute, “Most men with an elevated PSA test turn out not to have cancer; only 25 to 30 percent of men who have a biopsy due to elevated PSA levels actually have prostate cancer” [1]. This is because PSA is produced by prostate cells, whether they are malignant or benign and therefore, benign tumors also produce PSA in excess. Therefore, as noted in the Journal of the American Medical Association, PSA is not a suitable marker to screen asymptomatic men for prostatic cancer [2] and yet, for lack of a better test, it is used in regular checkups.

The PSA test is not specific enough to screen for prostate cancer. On the other hand, the high specificity exhibited by RECAF tests of prostate specimens, as well as in many other types of cancer, strongly supports the use of RECAF testing for screening.

Moreover, combining the PSA and RECAF tests could eliminate the false positives resulting from using PSA testing alone. PSA has the advantage of localizing the problem to the prostate and RECAF could then determine if the high PSA value is due to a cancer. This combination would also facilitate the introduction of RECA into the market place since PSA testing is very common. The company is discussing such a combination of tests with major healthcare companies and laboratories presently performing PSA tests.

PSA projected sales worldwide for 2004 are $450M [3] and prostate cancer represents only 17% of all cancers [4]. Our preliminary results indicate that RECAF works better than PSA for the detection of prostate cancer; and previous data showed that it could be used in most types of cancer. A simple extrapolation suggests a market potential for RECAF of $2.6B per year. To date, BioCurex has reported highly positive results from testing many forms of cancer including prostate, stomach, lung, ovary, breast and colon. These amount to 2/3 of all types of cancers and we believe that RECAF will work as well for the other 1/3 of malignancies.

Dr. Moro, BoCurex’s CEO, stated: “We are extremely happy to report these results, which were obtained with a new version of the company’s blood cancer detection assay. This improved test uses monoclonal antibody technology, for which Milstein and Kohler received the Nobel price in 1984. Monoclonal antibodies offer many significant advantages over the conventional antiserum test we were using previously to prove the RECAF concept. Monoclonals are far more specific, they are very consistent from one batch to another and they are easy to produce in industrial quantities using tissue culture techniques.”

The American Cancer Society estimates that over 220,000 men will be diagnosed with prostate this year in the U.S. with 29,000 deaths attributable to prostate cancer.

The company also wishes to advise that it is continuing its efforts to re-establish itself for quotation on the NASD OTC:BB. The process is not a direct one but the company is committed to the goal of achieving a more advanced listing. We appreciate the patience of our investors at this time and we will provide the investment community with appropriate updates as they occur.

BioCurex is also progressing with its plan to license its RECAF technology. A licensing agreement would allow the company to work with healthcare companies experienced in the cancer diagnostic arena and allow BioCurex to benefit from their scientific and business expertise.

To read more about the Company, please visit the News section in our web site (www.biocurex.com).

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the area of cancer diagnosis. The technology identifies a cancer marker known as RECAF[TM], which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB: BOCX), visit our website at www.biocurex.com.

Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are “forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.

Contact:

Ricardo Moro
BioCurex, Inc.
Tel: [phone]


References:
[1] Source: http://cis.nci.nih.gov/fact/5_29.htm
[2] Source : MD Krahn et al, Journal of the American Medical Association (JAMA), 1994 Sep 14;272(10):773-80.
[3] Source: The Worldwide Market for Cancer Diagnostics, November 2002. Market report published by Kalorama Information (http://www.kaloramainformation.com)
[4] Source: American Cancer Society, Cancer Facts and Figures 2004 (http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Fact…

[nekro]

Und aktuell schon +33%

[nekro]

+41%

[nekro]

SCHLUSS 0,75 +25%

[MrRipley]

Kennst Du dich mit Biotech aus?
Dein w:o Depot sieht ja ganz danach aus

[nekro]

Einer meiner einzigen BIOS

Aktuell 0,83 +36,07%

[nekro]

Im Hoch heute auf o,98 und 0 News zumindest finde ich keine

[nekro]

Mittlerweile auf 1$ +30%, immer noch ohne News,aber mit Riesenumsätzen (über 500 K )

Es sind verdächtig viele 10-20 K Order dabei
http://quotes.freerealtime.com/rt/frt/M?SA=quotes|Time%26Sal…

Beim letzten Ausbruch gings von 0,20 auf 3,70

http://quotes.freerealtime.com/rt/frt/M?SA=quotes|Chart&IM=q…

[nekro]

Heute 23 Trades über 10 K

Relisting,News oder Bluff

Dayhigh 1,10 Vol.680 K + 43,42 %

Das Wieso kann eigentlich egal sein

[nekro]

Hier die News


Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Press Release Source: BioCurex, Inc.


BioCurex Update
Friday February 25, 6:48 pm ET


RICHMOND, British Columbia, Feb. 25, 2005 (PRIMEZONE) -- As previously disclosed, BioCurex Inc. (Other OTC:BOCX.PK - News) intends to license its technology to companies involved in the manufacture, distribution and sale of cancer diagnostic products. The Company is progressing in its negotiations with third parties with respect to the licensing of two of the Company`s products. A Licensing Agreement has not been signed as of this date. The Company will keep investors updated as the situation progresses.
ADVERTISEMENT


BioCurex is continuing its efforts to advance its exchange listing. Unlike the process involved with listing on the NASDAQ, the AMEX or the NYSE, listing on the OTCBB involves a broker filing a Form 211 with the NASD. All communications pertaining to the 211 Form, supporting documentation and the listing process in general are strictly between the NASD and the broker submitting the 211 Form. Although the Company is not directly involved with the OTCBB listing process, the Company nevertheless cooperates with the broker in supplying answers concerning the Company which may be raised by the NASD. The Company recognizes the advantages of a more senior listing and will advise its investors progressively.

To read more about the Company, please visit the News section in our web site (http://www.biocurex.com).

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (Other OTC:BOCX.PK - News), visit our website at http://www.biocurex.com.

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.



Contact:
BioCurex, Inc.
Ricardo Moro
[phone]

[nekro]

Dayhigh 1,25 +8,7% Volumen 255 K

[TUENNES66]

Allen Investierten HZLGLW [/green Allen Investierten HZLGLW [/I

[nekro]

Und wieder ohne Neuigkeiten.

Schluss 1,55 +22,29% DH+Jahreshoch

Bis zu den nächsten 1000% ist`s zwar noch weit,die ersten 100 sind aber immerhin schon wieder geschafft

PS: Diese Aktie war schon mal mein erster 1000% er

[nekro]

Tageshoch heute 2USD

[MrRipley]

Wie kommts, dass Du immer wieder so gut Händle hast?

[nekro]

Meine Nieten poste ich nicht.

[nekro]

Jetzt hat der Global-Investor die doch tatsächlich auch schon entdeckt


+++ Strong Buy BioCurex von Montag, den 28. März 2005 +++




BioCurex Inc. (Symbol: BOCX)

+++ Revolutionäre Technologie zur Krebsfrüherkennung! +++

+++ Einstiegstiming nach Kurs- und Volumenanstieg ideal! +++


+++ Aufnahme von BioCurex ins GI-Musterdepot zum Kurs von 1,70 USD! +++




akt. Kurs: 1,70 USD
Kursziel: 4,00 USD
Börsenplatz: Other OTC BB
Rating: Strong Buy mit 135% Kurspotenzial !



Sehr geehrte Leserinnen und Leser,

nachdem Krebs zu Beginn des 20.Jahrhunderts in der Todesursachen-Statistik noch an siebter Stelle stand, gehen Fachleute davon aus, dass die Krankheit schon bald weltweit zur Todesursache Nummer 1 könnte. Obwohl Krebsspezialisten in aller Welt es seit Jahrzehnten intensiver Forschung versuchen, ist es ihnen bisher nicht gelungen, den Kampf gegen den Krebs endgültig zu gewinnen. Ein Tumor kann gutartig oder bösartig sein, oft weiß man dies aber erst, wenn man ihn herausoperiert und untersucht hat. Etwa 80 % aller Tumoren der Brust sind beispielsweise gutartig. Das Erschreckende an Tumorzellen ist, dass sie sich immer weiter teilen und vermehren. Es bildet sich eine sogenannte raumgreifende Geschwulst, die in das umliegende Gewebe oder Organ hineinwächst, es behindert und schließlich abtötet, weil die Geschwulst Platz braucht. Unser Körper besteht aus Tausenden Arten von Zellen, Sie werden sich vorstellen können, dass daher vergleichbar viele unterschiedliche Krebsformen vorkommen können. Manche Arten wachsen sehr langsam und "streuen" nicht , manche wachsen mit großer Geschwindigkeit und streuen viel, andere wiederum bilden keine soliden Tumoren – wie der Blutkrebs oder der Lymphkrebs.

Aus medizinischer Sicht gilt dabei für alle Krebsarten: Je früher die Erkrankung erkannt wird, umso größer sind die Heilungschancen. Gerade aus diesem Grund stellt die Früherkennung einen ganz wichtigen Bestandteil innerhalb der Krebsforschung dar. Unternehmen, die in diesem Bereich forschen und effektive Verfahren zur Früherkennung entwickeln, stehen bei unseren Analysten unter besonderer Beobachtung. Denn eines ist klar: Trotz enormer Fortschritte während der vergangenen Jahre ist der endgültige Durchbruch bisher noch nicht gelungen. Im Rahmen unseres heutigen Spezial Reports präsentieren wir Ihnen mit der US-amerikanischen BioCurex Inc. (Symbol: BOCX) deshalb ein Biotechnologieunternehmen, das im Bereich der Krebsforschung tätig ist und dabei insbesondere in der Früherkennung gerade in jüngster Vergangenheit enorme Forschritte machte. Die Voraussetzungen sind dabei klar: Gelingt es einem Unternehmen in der Krebsforschung einen signifikanten Schritt nach vorne zu machen, gibt es für den Aktienkurs dieser Gesellschaft kein Halten mehr. Andererseits sind die Risiken entsprechend höher als bei Biotechnologieunternehmen, die das Entwicklungs- und reine Forschungsstadium bereits hinter sich haben und mit einem oder mehreren Medikamenten auf dem Markt sind. Aber genau darin sehen wir bei BioCurex den Reiz. Spekulative Vollprofis sind sich der Risiken bewusst, sehen andererseits aber das gewaltige Kurspotenzial dieses Unternehmens.

Mit seiner patentierten Technologie ist BioCurex auf die Früherkennung von Krebserkrankungen spezialisiert, wobei die besondere Fähigkeit darauf beruht, Krebszellen von gesunden Zellen zu unterscheiden und diese dann einem besonderen Verfahren entsprechend zu behandeln. Ziel ist das Wachstum der Krebszellen zu blockieren, gleichzeitig aber keine gesunden Zellen zu beschädigen. Hintergrund ist dabei, mit der sogenannten RECAF Technologie diese Moleküle zu lokalisieren, die sich an Krebszellen, nicht aber an gesunden Zellen befinden. In Blut- und Gewebeuntersuchungen kann so eine Krebserkrankung diagnostiziert werden. Zudem ermöglicht es die RECAF- Technologie genau die Krebszellen zu behandeln und das Wachstum durch Medikamente und Antikörper zum Stillstand zu bringen, ohne dabei die gesunden Zellen zu schädigen. Von entscheidender Bedeutung ist dabei, dass dieses Verfahren auf alle Krebsarten angewandt werden kann. Als sogenannter Marker, ist RECAF ein Molekül, das nicht nur an der Oberfläche oder dem Inneren der Krebszellen auftritt, sondern ebenso im Blut von Krebspatienten. Im Gegensatz zu den meisten anderen Markern, durch die nur eine Krebsart nachgewiesen werden kann, ist RECAF ein weitverbreiteter Krebs-Marker, durch den eine Reihe von Krebsarten nachgewiesen werden können. Ganz besonders wichtig ist dabei, dass durch das Vorhandensein von RECAF auch Brust und Lungenkrebs, die gemeinsam rund 30% aller Krebserkrankungen ausmachen und für die es keinen effektiven Krebs-Marker gibt, nachgewiesen werden können.

Ohne Zweifel ein hochinteressantes Verfahren, das die Krebsforschung und insbesondere die Früherkennung einen enormen Schritt nach vorne bringen könnte. Dies scheint nun auch der breiten Öffentlichkeit nicht länger verborgen zu bleiben. Denn der Aktienkurs von BioCurex zog nach einer mehrmonatigen Seitwärtsbewegung zuletzt bereits deutlich an und durchbrach Ende Februar diesen Jahres die 1-USD-Marke. Aus charttechnischer Sicht ist dabei von besonderer Bedeutung, dass der jüngste Kursanstieg von einem kräftigen Anstieg des Handelsvolumens begleitet wird. Ein entscheidender Faktor bei der Wahl unseres Empfehlungszeitpunkts, da das anziehende Volumen dem Aufwärtstrend Stabilität und Nachhaltigkeit verleiht. Mit seiner hochinterssanten Story halten wir BioCurex schon länger auf unserer Watchlist. Doch erst das Momentum der vergangenen Wochen eröffnet dem spekulativ orientierten Anleger eine attraktive Einstiegsgelegenheit.







Wie dringend ein effektives Verfahren zur Früherkennung benötigt wird, zeigt dabei ein Blick auf die Statistiken, wobei allein in den USA 5 Millionen Krebspatienten während der vergangenen rund 10 Jahre starben. Über 8 Mio. Menschen leben mit Krebs, wobei Lungen- und Brustkrebs zusammen mit Leukämie zu den häufigsten Krebsarten zählen. Damit ist Krebs nach Herzerkrankungen noch die zweit häufigste Todesursache, wobei sich dies schon bald ändern könnte. Dabei könnten aber eine Vielzahl von Krebsarten geheilt werde, wenn sie nur früh genug erkannt werden. Und genau deshalb halten wir BioCurex mit seiner innovativen Technologie für ein so aussichtsreiches Investment. Das Unternehmen verfügt neben einem erfahrenen Managementteam über weltweit anerkannte Wissenschaftler und konnte im Bereich der Krebsfrüherkennung zuletzt ernorme Fortschritte erzielen.

Mit einer Marktkapitalisierung von knapp 50 Mio. USD sehen wir das Unternehmen selbst bei einer Kursverdoppelung attraktiv bewertet, wobei wir davon ausgehen, dass es für den Kurs kein Halten gibt, wenn sich die von BioCurex entwickelte Technologie langfristig am Markt etabliert. Aus diesem Grund nehmen wir die Aktie von BioCurex zusammen mit einer Strong-Buy-Empfehlung zum aktuellen Kurs von 1,70 USD ins Musterdepot des Global Investor auf!

Wie an dieser Stelle üblich möchten wir Sie neben dem Wachstumspotenzial, das sich in diesem Unternehmen verbirgt, andererseits auch darauf hinweisen, dass es sich bei BioCurex um ein High-Risk-Investment handelt, bei dem auch der Totalverlust nicht ausgeschlossen werden kann. Für unerlässlich halten wir es deshalb ein Stopp-Loss zu setzen. Sichern Sie Ihre Position im Bereich 1,29 USD ab. Berücksichtigen Sie zudem bei der Ordererteilung, Ihre Aufträge zu limitieren.

Die Aktie von BioCurex Inc. ist bisher lediglich in den USA unter dem Symbol BOCX handelbar wird dort zuletzt aber durchaus liquide gehandelt.

Ihr Team vom Global Investor !













Disclaimer:

Die in diesem Bericht gemachten Aussagen und Empfehlungen entsprechen ausschließlich der Meinung der Herausgeber zum Tag des Erscheinens. Sie beruhen auf sorgfältig recherchierten Quellen, die wir für glaubwürdig und zuverlässig halten. Wir geben keine Gewähr für die im Bericht gemachten Angaben und übernehmen keine Haftung für eventuelle Schäden, die durch Empfehlungen entstanden sind. Dieser Bericht dient ausschließlich Informationszwecken. Wir weisen ausdrücklich darauf hin, dass mit dem vorliegenden Bericht keinerlei verbindliche Beratungsleistung erbracht oder ersetzt werden kann. Der Verfasser ist nicht verantwortlich für Konsequenzen, speziell für Verluste, welche durch die Verwendung oder die Unterlassung der Verwendung aus den in diesen Berichten enthaltenen Meinungen und Rückschlüssen resultieren oder resultieren werden. Der Leser wird nachdrücklich aufgefordert, alle Behauptungen selbst zu überprüfen. Eine Anlage in die von uns vorgestellten, teilweise hochspekulativen Aktien sollte nicht vorgenommen werden, ohne vorher die aktuellsten Bilanzen und Vermögensberichte des Unternehmens bei der Securities and Exchange Comission (SEC) (=US-Börsenaufsichtsamt) unter der Adresse sec.gov zu lesen und anderweitige Unternehmensanalysen durchzuführen. Es kann nicht ausgeschlossen werden, dass die Dokumente im Auftrag des untersuchten Unternehmens erstellt worden sind. Anlagen in Aktien und Optionsscheinen beinhalten ein hohes Risiko und können in Einzelfällen zum Totalverlust führen. Dieses Werk inklusive aller seiner Teile ist urheberrechtlich geschützt. Jede Verwertung außerhalb der Grenzen des Urheberrechtes ist ohne eine ausdrücklich vorherige Zustimmung des Verfassers unzulässig und strafbar. Dies gilt insbesondere für Vervielfältigungen, Übersetzungen und die Eingabe in jegliche elektronische Medien sowie der damit verbundenen Darstellung gegenüber Dritten. Wir machen zudem darauf aufmerksam, dass es unseren Mitarbeitern nicht grundsätzlich untersagt ist, die Wertpapierempfehlungen unserer Fachabteilungen anzunehmen und selber eigene Positionen einzugehen. Diese Positionen können jederzeit – also vor, während und nach der Veröffentlichung von Analysen – ohne vorherige Bekanntgabe liquidiert werden, was unter Umständen einen belastenden Effekt für die Kursentwicklung bedeutet.

Da unsere Dienstleistungen des Finanzjournalismus und der Analyse für Aktienunternehmen und Kunden hier veröffentlicht werden und im Interessenkonflikt zur unabhängigen Analyse gedeutet werden müssen, teilen wir hiermit Folgendes mit: Die Leistungen des Global Investor (GI) umfassen den Finanzjournalismus und die Wertpapier- und Finanzmarktanalyse. Der GI betreut börsennotierte Aktiengesellschaften durch spezifische Research-Analysen oder regelmäßiges Coverage; durch Unternehmensanalysen und Branchenresearch. Dem GI kann diese Betreuung direkt oder indirekt finanziell durch die hier besprochenen Unternehmen honoriert werden.


Die Veröffentlichungen des Global Investors dürfen weder direkt noch indirekt in die USA, nach Kanada, nach Japan oder an deren Staatsangehörige verteilt werden. Die Veröffentlichungen des Global Investors dürfen in Großbritannien nur bestimmten Personen im Sinne des Financial Services Act 1986 zugänglich gemacht werden. Personen, die unsere Publikation erhalten, müssen diese und alle anderen Restriktionen beachten und sich hierüber entsprechend informieren. Werden diese Einschränkungen nicht beachtet, kann dies als Verstoß der jeweiligen Ländergesetze der genannten und analog dazu möglicherweise auch nicht genannter Länder gewertet werden.

[MrRipley]

[nekro]

Ganz frisch von heute :liAbbott and BioCurex Enter into Agreement for RECAF Cancer Technology
An emerging cancer biomarker, RECAF is found on malignant cells from a variety of cancer types and may be useful in the development of new cancer tests
3/29/2005 6:30:03 AM










ABBOTT PARK, Ill. & RICHMOND, British Columbia, Mar 29, 2005 (BUSINESS WIRE) -- Abbott and BioCurex (Pink Sheets:BOCX) today announced they have entered into a licensing agreement for BioCurex`s RECAF(TM) material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.







MARKETWATCH TOP NEWS
Greenberg retiring as AIG chairman
U.S. stocks end higher; blue chips snap four-day skid
Crude prices close above $54; analysts see $50
Qwest gives MCI until April 5 to accept offer




Sign up for FREE e-Newsletters




TRACK THESE TOPICS
My Portfolio Alerts
Company: Biocurex Inc Add
Create

Get Breaking News sent directly to your inbox




Create A Portfolio | Create An Alert

"Because many cancer deaths may be prevented with early screening and treatment, it`s important to develop new cancer tests that could more effectively target a specific type of cancer. Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott. "Abbott`s goal is to further develop this technology, incorporating it into future tests on our ARCHITECT(R) system, for use in cancer diagnosis and monitoring."

Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex`s RECAF technology. The agreement includes payment to BioCurex of up-front fees, product development milestones and royalties on any product sales. Other terms of the agreement were not disclosed.

"In terms of cancer detection and treatment, our RECAF technology has the potential to improve patient care due to its ability to differentiate cancer cells from healthy cells. Abbott is a worldwide leader in diagnostic testing, and we`re very excited to be able to work with them on implementing this technology with Abbott`s instruments for use in future cancer tests," said Ricardo Moro, M.D., chief executive officer, BioCurex.

According to the World Health Organization, more than 10 million people are diagnosed with cancer every year, and it is estimated that there will be 15 million new cases every year by 2020. The chance of cure increases substantially if cancer is detected early.

About BioCurex

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the area of cancer diagnosis, imaging and therapeutics. To find out more about BioCurex (BOCX.PK), visit www.biocurex.com.

About Abbott

Abbott has a strong history in cancer diagnostics. In 1991, Abbott developed the first automated PSA test for use on the IMx(R) System and has continued to expand cancer test menus across its diagnostic analyzers. Abbott`s innovative genomic tests include Vysis(R) UroVysion, which aids in diagnosing and monitoring bladder cancer, and PathVysion(R), for detecting amplification of the HER-2 gene to aid in determining whether a patient is an appropriate candidate for Herceptin(R) (trastuzumab) therapy for breast cancer.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries.

Abbott`s news releases and other information are available on the company`s Web site at www.abbott.com.

Note:

BioCurex Inc. has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.

SOURCE: BioCurex, Inc.


ck:

[MBA2005]

wo orderst du biocurex? mit meinem broker geht das nicht.

danke für die info

[nekro]

Ich habe sie über Consors geordert.

Müsste telefonisch aber überall möglich sein.


Akt.Jahreshoch 2.24 USD +18.52% Vol 450K

[MBA2005]

http://www.smallcapnetwork.net/archive/listserv/20050329-1.h…

bitte lesen!

[nekro]

Jetzt springt so langsam jeder Börsenbrief drauf

Hier der SmallcapDigest

Patience rewarded. Significant milestone achieved. Those two phrases encapsulate the importance of the joint announcement made today (release below) by biotech Biocurex (BOCX.PK) of the completion of a deal granting world-wide, semi-exclusive rights for its RECAF™ technology to healthcare giant Abbott Laboratories (NYSE: ABT).
Abbott has 60,000 employees, markets its products in more than 130 countries and posted almost $20 billion in annual sales in the past year.

Since we first brought Biocurex to the readership in October 2003 at 17 cents, the company has asked for investors’ patience and worked diligently to attract and sign significant partners with whom to license its cancer detection technology. Today’s announcement with behemoth Abbott Labs is a watershed for Biocurex and, we believe heralds the beginning of more deals as well as providing further validation of Biocurex’s cancer detecting RECAF™ technology.

Tuesday, in the joint Abbott/Biocurex press release the former announced that it “obtains worldwide, semi-exclusive rights to commercialize products using Biocurex’s RECAF™ technology”. The release further states that the work done by Biocurex may be “useful in the development of new cancer diagnostic tests”. Now that’s impressive. A large cap, quality partner who has the money and R&D muscle to advance RECAF’s™ importance as a tumor marker for the early detection of several types of cancer including prostate, breast, colorectal and lung.

It’s difficult to quantify the trading impact of today’s announcement within short-term technical guidelines. For those who hold shares, if there is a move up, a partial sale may be warranted to lower a cost base. For anyone who wades in to purchase, ensure that stop losses are in place as we suspect there will be significant volatility. Trade strategically is our best suggestion at this point. A core position should be maintained for the long term.

The shares have already moved up on deal speculation—especially on message boards such as Raging Bull-- over the past couple of weeks to close at $1.89, Monday. Depending on how the shares trade, the next resistance level looks to be around $2.60. If that level is breached convincingly, the shares could eventually try and retest the $3.90 level from last April. It won’t be dull, no matter what happens.

All we can say without fear of contradiction is that trading from Tuesday’s opening bell will be heavy. We suspect that there has been some shorting going on recently, and if there is a push in the BOCX stock price, covering may well add to the volatility as the naysayers get spanked, The quote for BOCX shares is here: http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX

Yes, this is an extremely BIG deal.

From the release:
“Abbott’s goal is to further develop this technology, incorporating it into future tests on our ARCHITECT® system, for use in cancer diagnosis and monitoring”.

ARCHITECT® is Abbott’s series of proprietary testing systems used for specific diagnostic regimens. By example, one of these regimens, the ARCHITECT® ci8200 system is described thusly:

Combining immunoassay and clinical chemistry on one integrated platform, the ci8200 system runs up to 200 immunoassay tests and up to 1200 clinical chemistry tests an hour. By consolidating both immunoassay and clinical chemistry testing capabilities, the ci8200 helps improve laboratory productivity and efficiency.

Once royalties begin to flow to Biocurex, the potential revenue generation, we believe, will be significant.

Three words: Deal = Enhanced Validation.

This deal is obviously a major corporate development for Biocurex. As well, in our opinion, the enhanced validation a deal such as this affords its technologies within the medical/diagnostic and pharmaceutical communities are likely beyond price.

Abbott apparently realizes, as does Biocurex, that this early cancer detection technology could well save a significant number of lives.

Specific details of the deal were not disclosed, but does include upfront fees, development milestones and royalties on any product sales. As Abbott is a worldwide leader in diagnostic testing, the potential for Biocurex is, to say the least, compelling. As well, in our opinion, this development should both advance the company’s current licensing discussions as well as bring further significant potential partners to the table.

Semi’s the word.

That brings us to the term ‘semi-exclusive’ within Tuesday’s release. Biocurex, for obvious reasons, is loath to grant exclusivity to any one company. Top-tier companies such as Abbott historically tend to want exclusivity. The fact that Abbott entered into a semi-exclusive arrangement, leaving Biocurex the right to enter into licensing arrangements with other companies, we believe, evidences the potential it sees in the technology and further enforces RECAF’s™ viability.

The other factor is that with Abbott on board to advance the RECAF™ technology, it allows Biocurex to focus and advance its technologies in the cancer imaging and therapy areas.

It’s only just begun…

Biocurex, through all its travails over the last year has never lost sight of the amazing potential of its technology for the early detection of cancer as well as the attendant cost savings to the healthcare sector. You may recall that just about a year ago, the shares charged up to $3.90 a share on daily volume in the tens of millions. The stock was subsequently halted by regulators for clarification of some claims and as a result of the halt was moved to the Pink Sheets in accordance with NASD rules. The company has and continues to cooperate fully with regulators. We are confident that a return to the OTCBB will occur in the not too distant future.

Now, with the announcement of Abbott signing on, it not only enhances the validity of the technology, but also bodes well for future deals and the ability for Biocurex to engage in more R&D to further expand its state of the art bio-technology and sector influence.

Over the months I’ve had several emails questioning the validity and viability of both Biocurex and its technology. My answer was always the same: be patient. It still is. We believe that this is only the beginning of the company’s technologies, current and future, that will eventually take their place in the forefront of early cancer detection and therapy.

As we have oft-said; patience is a virtue, especially in the smallcap market. You want patience? Today’s announcement is the

[Redpepper]

Hi,
so ich habe mich auch entschlossen nach längerem überlegen hier einzusteigen.
Denke, das uns dieses Sahnestück noch einige freude bereiten wird.
Die 2$ marke sollte die nächsten Tage dann auch durchbrochen werden und somit steht den 4$ nichts mehr im wege

Also ich bin von BioCurex Inc. überzeugt !!!
und die Nachrihten von den letzten Tagen sprechen auch für sich !!!

[Redpepper]

Biocurex wird nun so langsam von allen entdeckt !!!


SmallCapReview Introduces BioCurex

2005-03-29 09:29 ET - News Release

CHARLOTTE, N.C., March 29, 2005 (PRIMEZONE) -- SmallCapReview.com ( www.SmallCapReview.com ), a leading small-cap stock information site, introduces BioCurex (Pink Sheets:BOCX) to its database of subscribers and its website audience.

Abbott and BioCurex today announced they have entered into a licensing agreement for BioCurex`s RECAF(TM) material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

For more about BioCurex please visit http://www.smallcapreview.com/bocx.htm or the company`s website at http://www.biocurex.com

SmallCapReview.com news is a Free Newsletter sent to subscribers, highlighting select small-cap stocks. To sign-up visit http://www.smallcapreview.com/subscribe.htm.

Forward Looking Statements

Except for the historical information contained herein, the matters discussed in this release include certain forward-looking statements, which are intended to be covered by safe harbors. Investors are cautioned that all forward-looking statements involve risks and uncertainties including, without limitation, the factors detailed from time to time in company filings with the Securities and Exchange Commission. These factors could affect businesses and financial results in the future and could cause actual results to differ materially from plans and projections. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the company or any other person that objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available. We assume no obligation to update any forward-looking statements, except as required by law.

Disclosure: No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapReview.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on our web site. SmallCapReview.com has been compensated eight thousand five hundred dollars by a third party for its efforts in presenting the BioCurex profile on its web site and distributing it to its database of subscribers, this creates an inherent conflict of interest and readers are encouraged to view the full disclaimer at www.smallcapreview.com/bocx.htm.

CONTACT: SmallCapReview.com
Thomas Englebert, Editor
336-838-5005
[e-mail]

[MBA2005]

ganz schön was los da...
neue IR firma wird bald für otcbb relisting sorgen.

das kann noch was werden. aber morgen erstmal billig einkaufen...


gute nacht

[Redpepper]

Zwar schon ein paar Tage alt, zeigt aber wie alle von BOCX überzeugt sind !!
ATLANTA, GA, Mar 29, 2005 (MARKET WIRE via COMTEX) -- Market Pulse is pleased to introduce our featured stock, BioCurex, Inc. (OTC: BOCX), to the investment community! BioCurex is new to Market Pulse and is poised to become a significant player in the biotechnology industry! BOCX had great news out in a press release before today`s opening bell regarding Abbott and BioCurex today announcing they have entered into a licensing agreement for BioCurex`s RECAF(TM) material and technology! Investors should be watching this one closely!

BOCX ist auf dem Weg ein bedeutsamer Spieler in der Biotechnologie-Industrie zu werden !!!

[meislo]

Warum dann dieser Einbruch? aktuell 1,05 dollar!!

gruss meislo

[nekro]

:eekass es nach 200 % Kursanstieg zu Gewinnmitnahmen kommt ist völlig normal
Die Makler haben über 2 geschmissen und leicht über 1 wieder eingesammelt.
Jetzt diese Meldung

http://biz.yahoo.com/bw/050331/315726.html?.v=1

Akt. wieder 1,38

Es kann also wieder aufwärts gehen.
Auch dürfte das relisting demnächst wohl wieder anstehen.

[Redpepper]

@ #29 von nekro 01.04.05 02:33:56 Beitrag Nr.: 16.271.281
wann soll den das relisting anstehen ??
und wie sind eure weiteren einschätzungen was BOCX betrifft.
was bedeudet relisting---bin neu

[nekro]

BOCX ist vor ca 1 Jahr an der Nas.rausgeflogen (delisted)
Grund war ein "übersetzungsfehler" während den klinischen Tests ihres Produktes in einem chinesischen Krankenhaus.
Im Wortsinn wurde der Satz "Der Test ist zu 95% sicher beim entdecken von Prostata-u.Magenkrebs und lässt sich auch bei (allen)anderen Krebsarten einsetzen."
Daraufhin explodierte der Kurs um ca.1000%
Anderntags kamm dann die Meldung bei "allen" habe es sich um einen übersetzungsfehler gehandelt
darauf wurde der Handel erstmal einige Tage ausgesetzt,der Kurs sackte von ca.3,?? auf 0,5 ab.
Am Produkt hat sich jedoch nichts geändert.
Laut Angaben von BOCX arbeiten sie an der Wiedereinführung an der Nasdaq.

[groundh0g]

...die tage kommt wieder liqidität rein (sparvertrag wird fälllig), dann hol` ich mir ein paar :-)

[groundh0g]

...schon allein aus dem grund, weil das kürzel von Bougainville Copper (BOC) mit dem von Biocruex (BOCX) nahezu kongruent ist - ob das X bei Biocurex für um X-fach höhere gewinne als bei BOC steht? ich mag`s mir gar nicht ausmalen

nekro, bei dir sind die X-fach höheren gewinne ja bereits realität (..."mein erster 1000%er)

[MBA2005]

@Redpepper und alle interessierten

anruf bei aurelios (neue investor relations firma von bocx) ergab dass das relisting in den nächsten 30 tagen ansteht. ich hab heute nochmal nachgelegt, da ich diese kurse als für nicht gerechtfertigt niedrig ansehe. ein relisting wird wunder vollbringen, da ja gerade institutionelle investoren dann wieder einsteigen dürfen. ich glaube da warten einige sehnlichst drauf. unter 2 ist alles ein klarer kauf.

gruss

[Redpepper]

kann mir mal jemand sagen weshalb es in die falsche Richtung geht, tag für tag!!???!!

[nekro]

Wird in den nächsten Tagen für weitere Aufmerksamkeit sorgen

BTV will BROADCAST on KVOS TV, Channel 23,
an interview on BioCurex.

Please see below for your local stations and times.

BTV BROADCAST TIMES:
www.b-tv.com

CANADA:
Ontario: Toronto One - Sun. Apr. 10th @ 11:30pm EST
Alberta/Winnipeg/Brandon: A-Channel - Sun. Apr. 10th @ 11:30pm MST
BC/Washington: KVOS TV - Sun. Apr. 10th @ 4pm PST
Bell Express VU and Star Choice - West: A-Channels/TO One Sun. Apr. 10th @ 8:30pm PST

U.S.: - America One - Sun. Apr. 10th @11:00pm EST
www.americaone.com

WVVH South Hampton, NY
WSPY Plano, IL
WZBN Trenton, NJ
ShelbyTV Shelby Township
KKAX Kingman, AZ
WIVM Canton, OH
K48BK Dove Creek, CO
K27FA Craig, CO
WRCF Orlando, FL
WLLS Indiana
WLNN Boone, NC
W34AX Henderson, NC
W67CD Sanford, NC
WYBE Southern Pines, NC
WBKA Bucyrus, OH
KTYJ Coeur dAlene, ID
NSU22 Natchitoches, LA
WBCF Florence, AL
W35AY Hilton Head Island, SC
WJTS Jasper, IN
WGTN Worthington, MN
KCCE San Luis Obispo, CA
WBII Ashland, MS
WPRQ Clarksdale, MS
CTV12 Cedar City, UT
VTV Vernal, UT
KXOK Enid, OK
KXOC Oklahoma City, OK
KWEM Stillwater, OK
KEEN Las Vegas
KMCA Redding, CA
TV9 Troy, OH
CTV12 Cedar City, UT
VTV Vernal, UT
WBII Ashland, MS
WRBD Pensacola, FL
KDAO Marshalltown
W35BB Dublin, GA
IMAGE Erie, PA
KPIF Pocatello, ID
K23BJ Lake Havasu City, AZ
UPN23 Hornell, NY
WEBU Webb, MS
WLMO Lima, OH
WHAN Salem, IN

[Redpepper]

hi @ all,
hat jemand infos zu dem interview von BioCurex auf B-TV
??

[Redpepper]

hier könnt ihr das interview angucken. sehr interessant.
http://www.b-tv.com/s/GuestList.asp

[nekro]

Sieht gut aus

Jetzt fehlen nur noch Verträge.

[nekro]

Weitere soche Meldungen müssten dem Kurs wohl auf die Sprünge helfen

http://www.marketwatch.com/tools/quotes/newsarticle.asp?guid…
BioCurex`s RECAF Blood Test Detects 92 Percent of Cervical Cancers; Current Pap Smear Test Detects Only 55-80 Percent
4/15/2005 10:20:46 AM

RICHMOND, British Columbia, Apr 15, 2005 (PRIMEZONE via COMTEX) -- BioCurex, Inc. (Pink Sheets:BOCX) announced today that it had completed a study in which its RECAF blood test detected 92% of cervical cancers using a drop of blood. The specificity of the test was 95.7%. The study included 25 cervical cancer blood samples and 69 normal blood samples. Currently, there is no commercial blood test available for the detection of cervical cancer.





The National Cancer Institute reports a sensitivity of 55-88% for detecting high-grade lesions using a traditional Pap test (http://cancer.gov/cancertopics/pdq/screening/cervical/Health… (Certain changes in the diagnostic criteria -- combinations of reference thresholds -- may increase the Pap sensitivity to 70-80% with 95% specificity).

The 2005 estimated market size for Pap smears is $1 billion for 2005 (See Note). The diagnosis is performed under the microscope using vaginal material.

Dr. Ricardo Moro, BioCurex`s CEO stated, "We are very satisfied with these findings which are in line with our previous results for detecting other types of cancers. The accumulation of positive results strongly suggests that RECAF is expressed by all types of cancer thus lending additional support to the idea of using this cancer marker for routine cancer screening. A RECAF test performed on blood collected for other routine clinical analysis would likely prove much cheaper than the traditional pap test, which currently involves a gynecologist to extract the sample as well as a pathologist (or a sophisticated artificial intelligence system) to read the results. Another very important application for Biocurex`s blood test is to improve the follow-up screening of patients who have been operated on for cervical cancer; recurrence of the cancer or its metastases could be detected early by periodically monitoring the blood levels of RECAF, thereby significantly enhancing the chances of patient survival."

About cervical cancer:

Worldwide, cervical cancer claims around 190,000 lives annually, and is the third most common cause of cancer-related deaths. According to the American Cancer Society, the estimated number of women who will be diagnosed with invasive cervical cancer in 2005 is approximately 10,370 in the United States alone. About 3,710 women, the same source states, will die from cervical cancer.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com.

Additional Information:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.

Note: The Worldwide Market for Cancer Diagnostics, Nov. 2002 by Kalorama Information, a division of marketresearch.com.

[Redpepper]

@ #34 von MBA2005 06.04.05 00:44:07 Beitrag Nr.: 16.304.916

weis man schon was vom relisting?

noch jemand da?*gg*

also ich denke das ich bei diesen kurs noch ein paar stück nachlegen werde, was meint ihr?

[MBA2005]

warum aussteigen, wo alles gute erst bevorsteht!!
boxc wird sich als Abbott Partner auf einigen Experten Konferenzen in den USA präsentieren und für Aufsehen sorgen. Sollte dem shareprice ordentliche Sprünge bescheren.
Zum relisting noch nichts neues, warte jeden tag darauf.

hold your shares tight,

good luck

MBA

[Redpepper]

Press Release Source: BioCurex Inc.


BioCurex Presents Initiatives For The Next 12 Months
Thursday May 12, 9:30 am ET


RICHMOND, British Columbia--(BUSINESS WIRE)--May 12, 2005--BioCurex Inc. (Pink Sheets:BOCX - News) is pleased to provide information to its shareholders regarding its initiatives for the next 12 months of operation.
ADVERTISEMENT


BioCurex recently announced a licensing agreement with a global healthcare company for a selection of the diagnostic applications within our patented/proprietary RECAF technology. This agreement strongly validates our technology as well as its potential to provide information to the healthcare professional for the early detection of cancer within many differing tissue types.

In the past two years, we have concentrated our efforts on strengthening the company and developing tissue and blood tests to detect cancer. Our efforts have added significant shareholder value and built a solid platform for future growth.

On the technical side, during the same period, we developed a general RECAF blood test to detect cancer, which was licensed to a major healthcare company. During the next 12 months we expect that other major companies will follow suit due to the semi-exclusive nature of our licensing agreements. We are also actively pursuing the licensing of other blood tests, such as the RIA (radioimmunoassay) format we have developed, as well as a rapid test format similar to the well known pregnancy tests. Our firm belief is that these tests could be readily implemented in many countries.

Recent results indicate that we may be able to use our proprietary antibodies against RECAF for screening Pap smears for cervical cancer using microscopic examination. In the past few years, Pap tests have been increasingly done by automated systems using image recognition and artificial intelligence to discriminate between cancer cells and normal cells. Staining only the cancer cells using a variation of our Histo-RECAF(TM) test should prove very useful to markedly increase the productivity of automated systems as well as improving the accuracy of the final diagnosis. If our large sample studies are successful, we believe that a licensing deal could be struck within the next 12-18 months. In North America alone, 50 million Pap tests are carried out every year, representing a market of over $1B.

The Company recognizes that its RECAF technology can be utilized not only for in-vitro diagnosis but also for imaging and immunotherapy. The use of RECAF for imaging is under further investigation, research and development. The concept is to use a radioisotope to "label" a substance which then localizes on RECAF. Since RECAF is present on cancer cells but not on normal cells, the substance will identify the location of the cancer within the body. An image would then be taken to localize that cancer. The potential for this aspect of the technology to assist both diagnostics and ultimately therapeutics is significant, since knowing the location of the cancer is a further step in effective and early cancer management. We anticipate significant advancement in the imaging arena in the near term.

BioCurex`s ultimate goal is to provide directed therapy for cancer. The concept is to target the cancer cells expressing RECAF with our antibodies, either by themselves or coupled to chemotherapy drugs, toxins or radioactive compounds. Thus, only RECAF-positive cells, that is, cancer cells, would be killed; normal RECAF-negative cells would be spared. Preliminary in-vitro results suggest that this can be done, but further studies are required before making any definitive claims.

The Company has demonstrated its ability to license diagnostic applications of RECAF and will now embark on an efficient program to develop and subsequently enhance its therapeutic applications. The therapeutic program will be encompassing, but the potential reward for the company and obviously the patient population is enormous. We have attracted the interest of several research institutions and companies in the USA that wish to work with us on the different aspects of imaging and immunotherapy. The ultimate goal of these collaborations will be to engage in Phase I, II and IIII clinical trials.

Throughout our development period, the Company has fulfilled its financial needs with private equity investments with the issuance of restricted stock. The strategy has allowed us to minimize shareholder dilution. The financing of new initiatives is being pursued at this time. The establishment of income from the present long term royalty arrangement requires no further significant expenditure by the Company. Until the royalty revenue is established from the primary licensing deal, the Company will maintain an appropriate level of expenditure to accomplish its goals. The development of a RIA based serum test may well provide earlier revenues until licensing arrangements are achieved. Financing through additional strategic equity investment is anticipated. The Company has had several discussions on this subject to date. BioCurex will also focus on obtaining an alternative listing of its shares. The recent licensing agreement has provided new opportunities in this area.

We believe the potential for each RECAF application is very significant. Our diagnostic blood test is now validated. We are diversifying the effort to include several different RECAF applications with the final efforts concentrated on the most promising applications in order to minimize the risks. Our shareholders should recognize that the Company is on stable ground with recognized technology that has great potential to establish BioCurex as a major biotechnology company.

In summary, during the following 12-18 months the Company will emphasize its efforts to:

License its blood tests to other major companies
Develop and license a RECAF based test for manual and automated, high throughput PAP smear tests
Commence development of therapeutics and imaging applications based on RECAF
Develop collaborations and strategic alliances that will be instrumental in carrying out Phase I, II, and III clinical trials if and when the pre-clinical work for those imaging and therapeutic applications is successfully completed
License its proprietary RIA RECAF test to reference laboratories
Move the Company to a more appropriate listing of its shares.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com.

Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.



--------------------------------------------------------------------------------
Contact:
Fischer Health
Jennifer Brendel, 310-577-7870, Ext. 108 (Media)
or
Aurelius Consulting Group Inc
Dave Gentry, 800-644-6297, Ext. 104
Chris Bemudaz, 800-644-6297, Ext. 103
or
BioCurex Inc., 604-207-9150

[Redpepper]

Press Release Source: BioCurex, Inc.


BioCurex Inc. Discusses Company Strategy in Online Interview with AudioStocks.com
Friday May 13, 9:30 am ET


RICHMOND, British Columbia, May 13, 2005 (PRIMEZONE) -- BioCurex (Other OTC:BOCX.PK - News) is pleased to notify its shareholders that an online interview with the Company is available on AudioStocks.com, a financial information portal. The discussion reviews the corporate initiatives for the upcoming months, which includes further licensing of its blood tests to detect cancer. Further, using their validated RECAF technology, the company plans to refine the ability to image the locations of cancers in the body as well as advance the therapeutic applications.
BioCurex recently announced a significant licensing agreement with a global healthcare company for a selection of diagnostic applications of its patented/proprietary RECAF technology.

To listen to the interview, visit http://www.audiostocks.com/.

To read more about the Company, please visit the News section in our web site (http://www.biocurex.com).

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types, but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at http://www.biocurex.com.

ADVERTISEMENT


Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.



Contact:
Fischer Health
Jennifer Brendel
[phone], Ext. 108 (Media)

Aurelius Consulting Group Inc.
Dave Gentry
[phone], Ext. 104

Chris Bemudez
[phone], Ext. 103

BioCurex Inc.
[phone]


--------------------------------------------------------------------------------
Source: BioCurex, Inc.

[Redpepper]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Redpepper]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Redpepper]

kann mir mal jemand sagen was mit bocx abgeht??????

[Redpepper]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[MBA2005]

der dollar muss halten!! an sonsten bei 0,90 naechste unterstuetzung, dann werde ich auch wieder nachkaufen. momentan ist das ja zum heulen hier...
aber ich denke hier langfristig und da kann uns boxc noch ordentlich ueberraschen. davon bin ich ueberzeugt.

good luck

[nekro]

Even though there has not been a great deal of recent news from this biotech, BioCurex (BOCX.PK) saw renewed interest Tuesday as a result of some exposure through an Internet based newsletter. The shares popped to $1.43, Tuesday on decent volume and subsequently settled to close at $1.17. The shares opened Wednesday at $1.20.

In the release below, the company announced some quality publications that have written pieces regarding its technology. Links to the articles are at BioCurex’s website (www.biocurex.com) for readers to access. The life-blood of small biotechs is recognition in peer-reviewed journals and other like-oriented publications. The inclusion exposes the technology to significantly more potential R&D partners and licensees.

BOCX traded to the .382 retracement of the down move it’s had for a while, which was no surprise. However, if it can close above that .382 resistance, the next stop may very well be the .618 level. Of course if it breaks above that, it will most likely want to test the old high. The shares have been stuck in a range of 95 cents to $1.05 seemingly forever and, while yesterday’s action may not be the ultimate catalyst to break that trend, it definitely brought in more investors to the story and that’s also always a good thing.

The recent action evidences one thing for sure; new investors can obviously get just as excited as the rest of us once exposed to the company and it’s potential. While we are not aware of any solid timeline for the company to regain a more senior market listing, it is certainly foremost on the agenda. Again as we have oft stated, that eventuality will return the shares to more and larger radar screens.

Volumes have been creeping up of late, which is also a very positive sign. More news, more exposure should send it on its way, hopefully soon.

That said, even on the pinks, the potential for the company, in our view, remains amazing and feel that the shares continue to be undervalued when measured against that potential.

With the prolonged share price consolidation at or around the $1 level, it appears a floor or strong support level has been established and we continue to suggest that risk oriented long-term investors accumulate shares.
PRESS RELEASE
Press Release Source: BioCurex, Inc.

Peer Reviewed Journal Publishes RECAF Results.

RICHMOND, British Columbia, July 13, 2005, -- BioCurex Inc. (BOCX.PK - News) announced today the publication of its tissue and serum RECAF results in the last issue (June) of the journal IVD Technology (IVD is an acronym for In-Vitro Diagnostics, meaning clinical studies done on samples in a test tube).

The article was initially requested by IVDT in 2003 and it was originally limited to the detection of cancer cells on tissue sections. Publication was then postponed in order to include the results obtained on serum samples. The article’s title is “A new broad-spectrum cancer marker”.

IVDT has a circulation of 15,000 mostly among professional personnel in product R&D, design, manufacturing, quality assurance, regulatory affairs, and corporate management. All manuscripts are subjected to double-blind peer review to ensure the quality and relevance of the materials. The publisher disallows promotion of brands, products or services offered by authors.

In addition to the IVDT article, Hematology Oncology News & Issues interviewed Dr. Moro (BioCurex’s CEO) and as a result it published, in its May 2005 issue, a commentary on RECAF entitled: “RECAF biomarker for common cancers provides patient, doctor benefits”.

An excerpt of the article reads:”RECAF technology has the potential to benefit patients, doctors and the health care system by ruling out unnecessary and sometimes painful, biopsies; allowing oncologists to react promptly to elevated RECAF presence; and diagnosis patients at earlier stages.”

Hematology Oncology News & Issues is a NEWS magazine. Its charter is to report on the latest developments in these medical specialties and provide a forum for the exchange of ideas among the professional disciplines responsible for delivering care to the cancer patient.

Also, the May issue of ”View on Biotechnology” , a supporting publication to Pharmavoice, which reaches 17,000 US based life-sciences executives, dedicated its May issue to: ”Thought Leader Perspective. An overview of the biotechnology industry”. Dr. Moro was one of the 16 “thought leaders” interviewed.

None of the publications was paid for space, nor does BioCurex advertise in any of them. Links to the abovementioned publications can be found in the News section of our web site (www.biocurex.com).

Dr. Moro, President & CEO of BioCurex stated: “In the current business environment it is necessary but not sufficient to have an excellent technology; success ultimately depends on people - from the general public to industry leaders - learning about it. We are very glad to see the blood and tissue test results published in a peer reviewed publication that reaches not only scientists but also industry leaders.

We are well aware of the importance of communicating our results and achievements in many different forums including journals, congresses and industry magazines. These publications, together with the invitations we have received to discuss our results in the upcoming ISOBM congress suggest that people in our field are starting to take notice of our achievements. We shall continue our efforts in that direction.”

[MBA2005]

nekro

danke für die INformation. Ich hoffe, es kommt noch mehr positiver news flow. Wir sollten bald von den Pinks runterkommen, damit mehr Investoren in Biocurex investieren können.

Ich hoffe wir sehen dann bald den 2$ Kurs.

Gruss

[nekro]

Neue Studie unterhttp://www.smallcapdigest.net/news_images/bocx_research_repo…

[nekro]

http://americanbulls.com/StockPage.asp?CompanyTicker=BOCX&Ma…

30.05 +19,44%

BIOCUREX INC
Daily Commentary


Our system posted a BUY CONFIRMED today. The previous BUY recommendation that was confirmed was made on 10.17.2005 (78) days ago, when the stock price was 0.9000. Since then BOCX has fallen -4.44% .

Things are going O. K. nowadays. Another BUY signal is confirmed!

Did you find the chance to increase your shares? If so, take a deep breath and relax. Luck may be chasing you in these days.

Have you missed the chance to buy? Don`t worry. It isn`t after all very late for opening new positions. Hopefully, you will be able to find suitable prices for buying in the next session.


Candlestick Analysis
Today’s Candlestick Patterns:

White Opening Marubozu




Today a White Opening Marubozu was formed. This shows that the day opened and then the prices continued to go up all day long without coming below the opening level thus forming a long white body, however prices did not close at the high of the day and thus they created an upper shadow.

Definition:

The White Opening Marubozu is a single candlestick pattern characterized by a long white body. It has an upper shadow but no lower shadow. This is a strong bullish candlestick pattern.

[nekro]

Nachdem BOCX:PK monatelang um die 0,80 USD herumgedümpelt ist,kam gestern nach Boersenschluss mal wieder eine positive news.

Heute schon +60% im Top
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B38C…

BioCurex Blood Test Detects Very Early Stages of Breast Cancer With High Specificity

E-mail | Print | | Disable live quotes Last Update: 9:30 AM ET Apr 12, 2006


RICHMOND, British Columbia, Apr 12, 2006 (BUSINESS WIRE) -- BioCurex Inc. (Pink Sheets:BOCX) announced today that its RECAF blood test for cancer is able to detect very early stages of breast cancer with a high degree of accuracy.
The study was blinded in that the actual diagnosis was not disclosed to BioCurex until after the test was performed. All samples were verified as early stage cancers -- Stage I and Stage II. (There are four stages of cancer identifying the progression of the disease).
he table below shows the Sensitivity values with a specificity of 100% against normal patient samples (100% specificity means no false positives).
Cancer Stage(a) SENSITIVITY SPECIFICITY SAMPLES
--------------- ----------- ----------- -------
Stage I 90% 100% 42
Stage II 93% 100% 45



Dr. Moro, President, stated: "We are very pleased with the data presented, which are consistent with previous results obtained on tissue sections. The results unequivocally illustrate the potential RECAF has to offer for early cancer detection and we anticipate that the results for other cancer types will be consistent with these findings reported for breast cancer. This level of accuracy is particularly significant for a screening test since early detection is the key when it comes to fighting cancer.
"Previous reports have demonstrated the ability of RECAF to detect many types of cancer from tissue biopsy specimens and blood tests due to the presence of RECAF receptor on the surface of malignant cells, but not normal cells. However, using blood samples of verified early stage cancers, we can now further delineate the value of RECAF for the world population in a humanistic and economic fashion."
The following statistics illustrate the importance of early diagnosis in relation to the outcome of breast cancer: Patients diagnosed at Stage I have a 5 year survival of 87%. At Stage II the 5 year survival rate is still high (75%). Survival drops to 46% when the patient is diagnosed at Stage III and at Stage IV it is only 13%(b). It is well known that the costs to treat an early stage cancer are significantly less and the survival rate is much higher when a cancer is detected early.
The current standard for breast cancer screening is mammography. In the USA, the sensitivity of mammography to detect cancer is approximately 65-75% with 90% specificity (i.e. with 10% of false positives)(c). Medicare pays $135 for a digital mammogram and $85 for film(d).

[nekro]

Sent: Friday, April 28, 2006 11:00 AM
Subject: Biocurex news


> Thank you for your interest in BioCurex. As per your request we are sending you
> our latest new release.
>
>
> BioCurex Progresses
> Thursday April 27, 4:40 pm ET
>
> RICHMOND, British Columbia, April 27, 2006 (PRIMEZONE) -- Biocurex (Other OTC:BOCX.PK - News)
> is pleased to update its shareholders regarding its progress in various arenas:
> The recent announcement of our technology's ability to detect early stage breast
> cancer (Stage I and II) with over 90% sensitivity is excellent news for our
> shareholders. This result substantiates the long term work which we have done on
> tissue samples and particularly on blood samples. The new focus on early stage
> cancers came about due to a continued effort to improve the RECAF blood test in
> order to maximize the company's position in discussion with present and potential
> licensees. Our original test type was designed for ``proof of concept'' to
> biopharma companies, who would then incorporate our technology with their
> proprietary technology within their own systems. The licensing deal with Abbott
> Laboratories is based upon this principle.
>
> The Company has discussed terms with other potential licensees. These discussions
> were based on our ``proof of concept'' blood test and it became apparent that we
> would have a better negotiating position with large biopharma companies if a new
> test format was developed. Given the semi-exclusive nature of our licensing
> agreement with Abbott -- which effectively limits the number of licensees -- we
> have declined offers which could have negatively affected our overall royalty
> streams.
>
> We determined that a colorimetric blood test using RECAF for cancer detection
> would be simpler to use and more readily shipped to various labs and companies
> than our current test that employs low doses of radioactivity. The improvements
> resulting from this work have magnified the measured differences in serum values
> for RECAF between normal and cancer patients. This large difference between
> cancers and normal patients not only allows the detection of smaller tumors, (as
> recently shown for breast cancers where we can now detect 90% of early stages I
> and II); but it is also a requirement for a ``yes/no'' rapid test similar to a
> pregnancy test that could be used directly in the doctors' offices.
>
> There is good reason to believe that we can detect other types of early cancer
> with our new format. Therefore, if these results are confirmed for other
> malignancies, the work done in the past few months could result in a broad
> spectrum cancer test that could catch very early cancers; when they are mostly
> curable.
>
> Our focus on improving the technology has enhanced our opportunities for
> maximizing our negotiating position in licensing discussions. The new test format
> will be directly compatible with many of the larger biopharma companies'
> proprietary systems and that can expedite their evaluation since their workload
> to implement the test in their instruments would be minimal. Simply stated, ``the
> less work they have to do to adopt the technology, the more likely they are to
> license.''
>
> We have also advanced our science to improve cancer imaging, along the lines of
> the project with the Goshen Cancer Centre announced previously. This will also
> allow us to pursue the other uses of the technology including Therapeutics, where
> we have enticing preliminary results.
>
> Our efforts to expose the Company to the investment community are increasing and
> the Company continues to deliberately pursue alternative quotation of its shares.
>
> If our RECAF technology is exposed in progressive scientific publications and
> congresses in the future, we believe the medical arena will recognize the value
> of RECAF in assisting with the diagnosis of cancers in patients with symptoms;
> following patients who have had cancers in the past; screening the at-risk
> population. We thank our shareholders for their support and patience.
>
> About BioCurex:
>
> BioCurex, Inc. is a biotechnology company that is developing products based on
> patented/proprietary technology in the areas of cancer diagnosis, imaging and
> therapy. The technology identifies a cancer marker known as RECAF(TM), which is
> found on malignant cells from a variety of cancer types but is absent in most
> normal or benign cells.
>
> BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's
> RECAF(TM) Cancer technology. Studies from the investigators at BioCurex and
> elsewhere have reported a high level of clinical sensitivity and specificity for
> RECAF in many of the most common cancers, including prostate, breast, colorectal,
> lung and others.
>
> To read more about the Company, please visit the News section in our web site
> (http://www.biocurex.com).
>
> Note:
>
> The Company has not authorized the release of this information in any form that
> contravenes the Communication Act and will not be responsible for unsolicited
> massive distribution of this material by e-mail or facsimile by unauthorized
> parties. Statements in this press release, which are not historical facts, are
> ``forward-looking statements'' within the meaning given to that term in the
> Private Securities Litigation Reform Act of 1995. The Company intends that such
> forward-looking statements be subject to the safe harbors created thereby. Since
> these statements involve risks and uncertainties and are subject to change at
> any time, the Company's actual results could differ materially from expected
> results.
>
>
> Contact:
>
> BioCurex, Inc.
> Dr. Ricardo Moro
> [phone]
>
>
>
> BioCurex IR
>
> If you would no longer like to receive our news,
> please e-mail [e-mail] with Remove Request in the subject area.a.
>

[nekro]

Langsam aber sicher.....

Prostate Cancer Detected Very Early With RECAF Blood Test

Last Update: 5:37 PM ET May 16, 2006


RICHMOND, British Columbia, May 16, 2006 (PRIMEZONE via COMTEX) -- BioCurex Inc. (Pink Sheets:BOCX) announced today that its RECAF cancer test detects initial stages of prostate cancer with 75% sensitivity and 100% specificity when compared to healthy individuals; and 68% sensitivity with 97% specificity when compared to men with benign prostate conditions.
Sensitivity is the ability of a test to detect existing cancers (if all patients who have a cancer test positive = 100% sensitivity.) Specificity represents how well the test avoids false positives (no false positives = 100% specificity.)